Stock A086900 MEDY-TOX INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Medy-Tox Inc.

Equities

A086900

KR7086900008

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
132,500 KRW +3.43% Intraday chart for Medy-Tox Inc. -1.63% -45.02%
Mar. 21 Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 05 South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing MT

Business Summary

Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Company’s main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.

Number of employees: 728

Sales per Business

KRW in Million2022Weight2023Weight Delta
Biopharmaceutical Products
100.0 %
191,465 100.0 % 217,160 100.0 % +13.42%

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
36.8 %
66,704 34.8 % 79,821 36.8 % +19.66%
Asia
33.9 %
69,179 36.1 % 73,714 33.9 % +6.56%
America
22.2 %
43,633 22.8 % 48,297 22.2 % +10.69%
Middle East
3.9 %
4,929 2.6 % 8,536 3.9 % +73.19%
Europe
3.0 %
6,555 3.4 % 6,565 3.0 % +0.15%
Other
0.1 %
-- 227 0.1 % -

Managers

Managers TitleAgeSince
Hyun-Ho Jeong CEO
 Chief Executive Officer 61 00-05-01
Gi-Hyuk Yang CTO
 Chief Tech/Sci/R&D Officer 55 -
Hee-Seok Joo BRD
 Director/Board Member - -

Members of the board

Members of the board TitleAgeSince
Hyun-Ho Jeong CEO
 Chief Executive Officer 61 00-05-01
Gi-Hyuk Yang CTO
 Chief Tech/Sci/R&D Officer 55 -
Hee-Seok Joo BRD
 Director/Board Member - -
Dong-Hyeon Yoo BRD
 Director/Board Member 63 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 440,635 0 0 67.83 %
Stock B 1 7,298,468 4,950,584 ( 67.83 %) 568,242 ( 7.786 %)
Stock C 0 21 0 21 ( 100.00 %)

Shareholders

NameEquities%Valuation
Hyun-Ho Jeong
18.12 %
1,322,523 18.12 % 143 M ₩
MEDY-TOX INC.
7.801 %
569,340 7.801 % 62 M ₩
Goldman Sachs Asset Management International
0.2974 %
21,705 0.2974 % 2 M ₩
Gyeong-hee Park
0.1827 %
13,336 0.1827 % 1 M ₩
Pension Reserves Investment Management Board
0.1714 %
12,511 0.1714 % 1 M ₩
Jae-wook Kim
0.1110 %
8,099 0.1110 % 875 324 ₩
FIL Asset Management (Korea) Ltd.
0.0989 %
7,216 0.0989 % 779 891 ₩
Credit Suisse Asset Management LLC
0.0796 %
5,806 0.0796 % 627 501 ₩
Korea Investment Management Co., Ltd.
0.0634 %
4,626 0.0634 % 499 969 ₩
Mirae Asset Global Investments Co., Ltd.
0.0283 %
2,069 0.0283 % 223 613 ₩
NameEquities%Valuation
Dominus Investment Co., Ltd.
80.74 %
440,635 80.74 % 48 M ₩
MEDY-TOX INC.
0.003848 %
21 0.003848 % 2 270 ₩

Holdings

NameEquities%Valuation
MEDY-TOX INC.
7.80%
 569,340 7.80% 61,533,123 $

Company contact information

Medy-Tox, Inc.

78 Gangni 1-gil Ochang-eup

28126, Cheongwon-gun

+

http://www.medy-tox.co.kr
address Medy-Tox Inc.(A086900)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Medy-Tox Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
132,500 KRW
Average target price
296,000 KRW
Spread / Average Target
+123.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
MEDY-TOX INC. Stock Medy-Tox Inc.
-45.02% 623M
CSL LIMITED Stock CSL Limited
-5.32% 84.57B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 39.93B
BIOGEN INC. Stock Biogen Inc.
-26.37% 27.93B
UCB Stock UCB
+52.09% 24.21B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-6.59% 17.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-32.37% 13.93B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-10.45% 12.3B
INCYTE CORPORATION Stock Incyte Corporation
-15.88% 11.84B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-2.85% 7.91B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A086900 Stock
  4. Company Medy-Tox Inc.